Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 31 Aug 2019 Planned End Date changed from 1 Apr 2021 to 31 Aug 2021.
- 31 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2019 Planned End Date changed from 31 Aug 2021 to 1 Aug 2022.